New Anaphylaxis Nasal Spray Hampered by Formulary Delays
The introduction of a new intranasal adrenaline spray for anaphylaxis management has faced delays in being included in NHS formularies. Healthcare professionals are prepared to prescribe the spray, which is seen as a significant advancement in treating anaphylaxis. The new delivery method aims to reduce hesitancy in administering adrenaline and improve patient outcomes.
- ▪The intranasal adrenaline spray, EURneffy, has been approved by the MHRA but is still not widely available for prescription.
- ▪Healthcare professionals believe this new method will change how anaphylaxis is managed in both community and hospital settings.
- ▪Intranasal adrenaline is a needle-free option that may appeal to those reluctant to use autoinjectors.
Opening excerpt (first ~120 words) tap to expand
BIRMINGHAM, UK — Despite being approved by the Medicines and Healthcare products Regulatory Agency (MHRA) almost a year ago, some NHS practices are still waiting to be able to prescribe the first available intranasal adrenaline (EURneffy) to their patients at high risk for anaphylaxis. “We've got our data to support what we're doing; we've got all our plans in place; we've changed our consent forms already. You know, everyone's got devices, we're trained and ready to go, but we just need to start getting the product,” paediatric allergy nurse Rebecca Batt told Medscape News UK. Batt who works for Evelina London Children's Hospital, part of Guy's and St Thomas' NHS Foundation Trust, said the delay was largely down to getting the drug on to local practices’ formularies.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
